清髓后自体造血干细胞移植可逆转系统性硬化症分子特征
基于SCOT随机试验中62名系统性硬化症患者,比较清髓联合自体造血干细胞移植(HSCT)与每月静脉环磷酰胺(CYC)对全血转录组和血清蛋白的影响。HSCT组在26个月时干扰素和中性粒细胞模块显著下降、细胞毒性/NK模块上升,而CYC组无显著变化;分子特征改善与肺功能及皮肤评分改善相关。
要点
- HSCT后26个月干扰素和中性粒细胞转录模块显著下降,细胞毒性/NK模块上升。
- CYC对照组上述分子模块无显著变化。
- 干扰素/中性粒细胞模块下降与肺活量改善相关,细胞毒性/NK模块上升与皮肤评分改善相关。
核心结论
- 清髓后自体HSCT相比常规CYC治疗可显著纠正系统性硬化症相关分子特征。
研究设计与样本
- 基于SCOT随机试验(NCT00114530)中62名系统性硬化症患者,在基线、随机后8个月和26个月进行全血转录组(Illumina HT-12芯片)和102种血清蛋白检测。
主要发现
- 基线时系统性硬化症患者相比未受影响对照,干扰素和中性粒细胞转录模块上调,细胞毒性/NK模块下调。
- HSCT组26个月对比基线,干扰素和中性粒细胞模块显著下降,细胞毒性/NK模块上升;CYC组无显著变化。
- 与干扰素和中性粒细胞转录模块相关的血清蛋白复合评分及多水平分析显示HSCT后分子特征显著变化,CYC组未观察到类似变化。
- 干扰素和中性粒细胞模块下降与肺用力肺活量改善相关,细胞毒性/NK模块上升与皮肤评分改善相关。
临床怎么用
- HSCT可考虑用于系统性硬化症患者以纠正疾病相关分子特征,但需结合临床结局综合评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: In the randomised scleroderma: Cyclophosphamide Or Transplantation (SCOT trial) (NCT00114530), myeloablation, followed by haematopoietic stem cell transplantation (HSCT), led to improved clinical outcomes compared with monthly cyclophosphamide (CYC) treatment in systemic sclerosis (SSc). Herein, the study aimed to determine global molecular changes at the whole blood transcript and serum protein levels ensuing from HSCT in comparison to intravenous monthly CYC in 62 participants enrolled in the SCOT study. METHODS: Global transcript studies were performed at pretreatment baseline, 8 months and 26 months postrandomisation using Illumina HT-12 arrays. Levels of 102 proteins were measured in the concomitantly collected serum samples. RESULTS: At the baseline visit, interferon (IFN) and neutrophil transcript modules were upregulated and the cytotoxic/NK module was downregulated in SSc compared with unaffected controls. A paired comparison of the 26 months to the baseline samples revealed a significant decrease of the IFN and neutrophil modules and an increase in the cytotoxic/NK module in the HSCT arm while there was no significant change in the CYC control arm. Also, a composite score of correlating serum proteins with IFN and neutrophil transcript modules, as well as a multilevel analysis showed significant changes in SSc molecular signatures after HSCT while similar changes were not observed in the CYC arm. Lastly, a decline in the IFN and neutrophil modules was associated with an improvement in pulmonary forced vital capacity and an increase in the cytotoxic/NK module correlated with improvement in skin score. CONCLUSION: HSCT contrary to conventional treatment leads to a significant 'correction' in disease-related molecular signatures.
引用
- Assassi S, Wang X, Chen G, et al. Myeloablation followed by autologous stem cell transplantation normalises systemic sclerosis molecular signatures. Ann Rheum Dis. 2019. PMID: 31391177. doi:10.1136/annrheumdis-2019-215770
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。